Publicacións en colaboración con investigadores/as de Memorial Sloan Kettering Cancer Center (23)

2024

  1. A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies

    OncoImmunology, Vol. 13, Núm. 1

  2. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆

    Annals of Oncology, Vol. 35, Núm. 2, pp. 159-182

2022

  1. First international workshop of the ATM and cancer risk group (4-5 December 2019)

    Familial Cancer, Vol. 21, Núm. 2, pp. 211-227

2021

  1. ALK-negative anaplastic large cell lymphoma: Features and outcomes of 235 patients from the International T-Cell Project

    Blood Advances, Vol. 5, Núm. 3

2020

  1. Proceedings From the First International Workshop at Sidra Medicine: “Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development”, 15th–16th February 2019, Doha, Qatar

    Frontiers in Immunology, Vol. 11

2018

  1. Prediction of acute myeloid leukaemia risk in healthy individuals

    Nature, Vol. 559, Núm. 7714, pp. 400-404

2016

  1. The impact on survival of an extensive sex cord-like component in mullerian adenosarcomas: A study comprising 6 cases

    International Journal of Gynecological Pathology, Vol. 35, Núm. 2, pp. 147-152

2014

  1. Reproducibility of current classifications of endometrial endometrioid glandular proliferations: Further evidence supporting a simplified classification

    Histopathology, Vol. 64, Núm. 2, pp. 284-292

2011

  1. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials

    The Lancet, Vol. 378, Núm. 9793, pp. 771-784

  2. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials

    The Lancet, Vol. 378, Núm. 9793, pp. 771-784

2010

  1. Characterization of the human Activin-A receptor type II-like kinase 1 (ACVRL1) promoter and its regulation by Sp1

    BMC Molecular Biology, Vol. 11

2009

  1. Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 106, Núm. 51, pp. 21830-21835

  2. Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma

    BMC Cancer, Vol. 9

2007

  1. Comprehensive analysis of tumoral DNA content reveals clonal ploidy heterogeneity as a marker with prognostic significance in locoregional neuroblastoma

    Genes Chromosomes and Cancer, Vol. 46, Núm. 4, pp. 385-396

2005

  1. EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma

    Cancer Research, Vol. 65, Núm. 7, pp. 2565-2571

  2. Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma

    Cancer Immunology, Immunotherapy, Vol. 54, Núm. 4, pp. 400-406

  3. Prognostic value of MYCN and ID2 overexpression in neuroblastoma

    Pediatric Blood and Cancer, Vol. 45, Núm. 7, pp. 909-915

2004

  1. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma

    Journal of the National Cancer Institute, Vol. 96, Núm. 16, pp. 1208-1219

  2. Comprehensive analysis of the 9p21 region in neuroblastoma suggests a role for genes mapping to 9p21-23 in the biology of favourable stage 4 tumours

    British Journal of Cancer, Vol. 91, Núm. 6, pp. 1112-1118

  3. Positional gene expression analysis identifies 12q overexpression and amplification in a subset of neuroblastomas

    Cancer Genetics and Cytogenetics, Vol. 154, Núm. 2, pp. 131-137